Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Part of paid clinical trials in Tucson, Arizona.

Sponsor
Immunovant Sciences GmbH
Study ID
NCT07032662
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Chronic Inflammatory Demyelinating Polyneuropathy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Imeroprubart — DRUG
    Dose 1 subcutaneous (SC) once weekly (QW) for 24 weeks (Period 1) and 52 weeks (Period 2)
  • Placebo — DRUG
    Matching placebo SC QW for 24 weeks (Period 1)

Study Details

This is a Phase 2b study to evaluate the efficacy and safety of Imeroprubart in adults with CIDP.

Key Dates

Start date
Mar 18, 2025
Status verified
Jun 2026
Primary completion
Aug 31, 2028
Completion
May 31, 2030

Study Design

Enrollment
162 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Imeroprubart
  • Placebo Comparator: Placebo

Primary Outcome Measure

Proportion of participants remaining Relapse-free by Week 24 [ Time Frame: Baseline, Week 24 ]

Central Contacts

Locations (31)

FacilityCityStateZIPSite coordinators
Site Number - 1612TucsonArizona85718-
Site Number - 1618CarlsbadCalifornia92011-
Site Number - 1619OrangeCalifornia92868-
Site Number - 1607Rancho MirageCalifornia92270-
Site Number -1608San FranciscoCalifornia94109-
Site Number - 1626ParkerColorado80138-
Site Number - 1621New HavenConnecticut06511-
Site Number - 1601Washington D.C.District of Columbia20037-
Site Number - 1630Washington D.C.District of Columbia20010-
Site Number - 1603MaitlandFlorida32751-
Site Number - 1606MiamiFlorida33136-
Site Number - 1617Ormond BeachFlorida32174-
Site Number - 1620Port CharlotteFlorida33952-
Site Number - 1633RockledgeFlorida32955-
Site Number - 1602Kansas CityKansas66205-
Site Number - 1611NicholasvilleKentucky40356-
Site Number - 1623BostonMassachusetts02114-
Site Number - 1625WorcesterMassachusetts01655-
Site Number - 1629DetroitMichigan48201-
Site Number - 1634Las VegasNevada89106-
Site Number - 1605New YorkNew York10032-
Site Number - 1627New YorkNew York10065-
Site Number - 1635Chapel HillNorth Carolina27514-
Site Number - 1610CharlotteNorth Carolina28204-
Site Number - 1624CantonOhio44718-
Site Number - 1631YukonOklahoma73099-
Site Number - 1614PortlandOregon97239-
Site Number - 1616PhiladelphiaPennsylvania19107-
Site Number - 1622HoustonTexas77030-
Site Number - 1628San AntonioTexas78229-
Site Number - 1613MilwaukeeWisconsin53226-

Find similar trials in Tucson, AZ

By research site
Site Number - 1612· Tucson, AZSite Number - 1618· Carlsbad, CASite Number - 1619· Orange, CASite Number - 1607· Rancho Mirage, CASite Number -1608· San Francisco, CASite Number - 1626· Parker, CO

Related Studies